Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has granted Fast Track Designation to safusidenib, an investigational oral brain-penetrant IDH1 inhibitor, for IDH1-mutant glioma. Phase 2 data from 27 patients showed a 51.9% objective response rate and a 36-month progression-free survival rate of 79.1%, with responses remaining durable at nearly 40 months of follow-up. The drug is now advancing into a pivotal phase 3 program.
The FDA has granted Fast Track Designation to safusidenib — an investigational oral, brain-penetrant, selective inhibitor of mutant IDH1 — for the treatment of IDH1-mutant glioma. Developed by Nuvation Bio, the designation reflects the drug's potential to address a significant unmet need in a patient population where the disease remains incurable despite generally more favorable survival compared to IDH wild-type tumors.
The designation follows updated long-term data from the phase 2 J201 study in 27 chemotherapy- and radiotherapy-naïve patients with grade 2 IDH1-mutant glioma in Japan. After nearly 40 months of follow-up, responses continued to deepen and no new safety signals emerged. Safusidenib is now advancing into multiple phase 3 and phase 2 trials across newly diagnosed and post-vorasidenib settings.
By the Numbers:
Why it matters: Many glioma patients are in their 30s–50s with jobs and families. A targeted, tolerable therapy that could delay or reduce exposure to radiation and chemotherapy — while maintaining disease control — would be a meaningful advance for this population.
